EU/3/07/516

Table of contents

About

On 20 December 2007, orphan designation (EU/3/07/516) was granted by the European Commission to SymbioTec GmbH, Germany, for recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3 for the treatment of acute myeloid leukaemia.

The sponsorship was transferred to Xenetic Biosciences Plc, United Kingdom, in October 2012.

Key facts

Active substance
Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3
Disease / condition
Treatment of acute myeloid leukaemia
Date of first decision
20/12/2007
Outcome
Positive
EU designation number
EU/3/07/516

Sponsor's contact details

Xenetic Biosciences Plc
London Bioscience Innovation Centre
2 Royal College Street
London
NW1 0NH
United Kingdom
Tel. +44 (0)20 7691 4906
Fax +44 (0)20 7916 9771
E-mail: bd@xeneticbio.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating